UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Directing dendritic cell immunotherapy towards successful cancer treatment

Immunotherapy, 2010-01, Vol.2 (1), p.37-56

2010

Volltextzugriff (PDF)

Cancer immunotherapy: dendritic-cell vaccines on the move

Nature (London), 2015-03, Vol.519 (7543), p.300-301

2015

Volltextzugriff (PDF)

Evidence of dysregulation of dendritic cells in primary HIV infection

Blood, 2010-11, Vol.116 (19), p.3839-3852

2010

Volltextzugriff (PDF)

In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection

PloS one, 2009, Vol.4 (1), p.e4256

2009

Volltextzugriff (PDF)

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

Journal for immunotherapy of cancer, 2018-05, Vol.6 (1), p.38-38, Article 38

2018

Volltextzugriff (PDF)

Dendritic cell immunotherapy

Annals of the New York Academy of Sciences, 2013-05, Vol.1284 (1), p.31-45

2013

Volltextzugriff (PDF)

Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy

Journal of visualized experiments, 2013-08 (78)

2013

Volltextzugriff (PDF)

Differential Impairment of Lytic and Cytokine Functions in Senescent Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes

Journal of Virology, 2003-03, Vol.77 (5), p.3077-3083

2003

Volltextzugriff (PDF)

Dendritic-cell vaccines on the move

Nature (London), 2015-03, Vol.519 (7543), p.300-301

2015

Volltextzugriff (PDF)

Dendritic Cell Vaccines

Methods in molecular biology (Clifton, N.J.), 2016-01, Vol.1403, p.763

2016

Volltextzugriff (PDF)

Impacts of Epitope Expression Kinetics and Class I Downregulation on the Antiviral Activity of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes

Journal of Virology, 2004-01, Vol.78 (2), p.561-567

2004

Volltextzugriff (PDF)

Genetic and Stochastic Influences on the Interaction of Human Immunodeficiency Virus Type 1 and Cytotoxic T Lymphocytes in Identical Twins

Journal of Virology, 2005-12, Vol.79 (24), p.15368-15375

2005

Volltextzugriff (PDF)

Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype

The Journal of clinical investigation, 2011-03, Vol.121 (3), p.1088-1101

2011

Volltextzugriff (PDF)

Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

Cancer immunology research, 2020-01, Vol.8 (1), p.70-80

2020

Volltextzugriff (PDF)

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma

Cancer immunology research, 2015-03, Vol.3 (3), p.278-287

2015

Volltextzugriff (PDF)

Trials in progress: A phase II study of in situ therapeutic vaccination against refractory solid cancers with intratumoral poly-ICLC

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.166-166

2017

Volltextzugriff (PDF)

Treatment of solid tumors with intratumoral poly-ICLC: A phase II clinical study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e14010-e14010

2014

Volltextzugriff (PDF)

Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3084-3084

2016

Volltextzugriff (PDF)

In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3086-3086

2016

Volltextzugriff (PDF)

A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS3114-TPS3114

2017

Volltextzugriff (PDF)

Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in high-risk melanoma patients

Cancer immunology research, 2019-11, Vol.8 (1), p.70-80

2019

Volltextzugriff (PDF)

Clonal breadth of the HIV-1-specific T-cell receptor repertoire in vivo as determined by subtractive analysis

AIDS (London), 2005-06, Vol.19 (9), p.887-896

2005

Volltextzugriff (PDF)

Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e20025-e20025

2014

Volltextzugriff (PDF)

Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS9119-TPS9119

2014

Volltextzugriff (PDF)

Detection of HIV-1-specific CTL responses in Clade B infection with Clade C Peptides and not Clade B consensus peptides

Journal of immunological methods, 2005, Vol.296 (1), p.1-10

2005

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(34)
Dissertationen
(1)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

Humans
(18)
Science & Technology
(18)
Life Sciences & Biomedicine
(15)
Immunology
(10)
Virology
(7)
Hiv-1 - Immunology
(6)
T-Lymphocytes, Cytotoxic - Immunology
(6)
Biological And Medical Sciences
(5)
Cancer Vaccines - Immunology
(5)
Dendritic Cells
(5)
Dendritic Cells - Immunology
(5)
Female
(5)
Infectious Diseases
(5)
Male
(5)
Cancer
(4)
Cd8-Positive T-Lymphocytes - Immunology
(4)
Hiv
(4)
Human Immunodeficiency Virus 1
(4)
Human Viral Diseases
(4)
Immune System
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Directing dendritic cell immunotherapy towards successful cancer treatment

Cancer immunotherapy: dendritic-cell vaccines on the move

Evidence of dysregulation of dendritic cells in primary HIV infection

In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

Dendritic cell immunotherapy

Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy

Differential Impairment of Lytic and Cytokine Functions in Senescent Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes

Dendritic-cell vaccines on the move

Dendritic Cell Vaccines

Impacts of Epitope Expression Kinetics and Class I Downregulation on the Antiviral Activity of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes

Genetic and Stochastic Influences on the Interaction of Human Immunodeficiency Virus Type 1 and Cytotoxic T Lymphocytes in Identical Twins

Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype

Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma

Trials in progress: A phase II study of in situ therapeutic vaccination against refractory solid cancers with intratumoral poly-ICLC

Treatment of solid tumors with intratumoral poly-ICLC: A phase II clinical study

Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma

In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study

A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers

Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in high-risk melanoma patients

Clonal breadth of the HIV-1-specific T-cell receptor repertoire in vivo as determined by subtractive analysis

Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma

Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma

Detection of HIV-1-specific CTL responses in Clade B infection with Clade C Peptides and not Clade B consensus peptides

Suchergebnisse filtern